0
Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
0 Vote
1 Contributor
1568 Views 
0 Saved
0 Vote 1 Contributor1568 Views 0 SavedYou might also be interested in
Understanding the difference between chemotherapy and radiation treatment can help you be more prepared for visits to your doctor. Various treatment options are available for patients suffering from cancer. Based on the type and stage of cancer, when the patient is diagnosed, patient’s overall he....
A benign tumor means it’s not cancer. These tumors don’t spread to other parts of the body and are usually not life-threatening. However, depending on their size or location, they may need to be removed if they press on important organs or cause discomfort.
Dear sir, I have suffering from Peptic ulcer from 7 years back and still now, if there any treatment from ur hand so please kindly suggest me.
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.